SCHEMBL1235186

SCHEMBL1235186

Cc1cc(C)nc(N(C)S(=O)(=O)c2ccc(NC(=O)NC(=O)c3ccc(Cl)cc3Cl)cc2)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PCTP Q9UKL6 12/20 1.00
STARD10 Q9Y365 6/20 1.00
STARD7 Q9NQZ5 1/20 0.71
GPR27 Q9NS67 2/20 0.58
PYGL P06737 3/20 0.53
AVPR2 P30518 1/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
CA9 Q16790 1/20 0.51
LMNA P02545 1/20 0.50
GAA P10253 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17280988 0.86 PCTP (0.75) PCTPSTARD10STARD7GPR27PYGL
SCHEMBL16685617 0.85 PCTP (0.75) PCTPSTARD10STARD7GPR27LMNA
SCHEMBL1235824 0.84 PCTP (0.72) PCTPSTARD10STARD7GPR27PYGL
SCHEMBL1233504 0.83 PCTP (1.00) PCTPSTARD10STARD7GPR27AVPR2
SCHEMBL1235093 0.78 PCTP (1.00) PCTPSTARD10STARD7LMNAGAA
SCHEMBL1234435 0.78 PCTP (1.00) PCTPSTARD10STARD7GPR27AVPR2
SCHEMBL1235844 0.76 PCTP (1.00) PCTPSTARD10STARD7GPR27PYGL
SCHEMBL13470344 0.75 PCTP (0.60) PCTPSTARD10STARD7PYGLLMNA
SCHEMBL13470343 0.75 PCTP (0.85) PCTPSTARD10STARD7GPR27LMNA
SCHEMBL1235845 0.74 PCTP (1.00) PCTPSTARD10STARD7GPR27PYGL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190201420-A1 METHODS OF PREVENTION OR TREATMENT FOR PATHOLOGIC THROMBOSIS OR INFLAMMATION THOMAS JEFFERSON UNIVERSITY (US) 2019-07-04 US claimed
US-20160271150-A1 METHODS OF PREVENTION OR TREATMENT FOR PATHOLOGIC THROMBOSIS OR INFLAMMATION THOMAS JEFFERSON UNIVERSITY (US) 2016-09-22 US claimed
US-9126938-B2 Phosphatidylcholine transfer protein inhibitors THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2015-09-08 US claimed
WO-2015065876-A1 METHODS OF PREVENTION OR TREATMENT FOR PATHOLOGIC THROMBOSIS OR INFLAMMATION THOMAS JEFFERSON UNIVERSITY (US) 2015-05-07 WO claimed
US-20120264756-A1 Phosphatidylcholine Transfer Protein Inhibitors THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2012-10-18 US claimed
EP-2467362-A2 PHOSPHATIDYLCHOLINE TRANSFER PROTEIN INHIBITORS The Brigham and Women's Hospital, Inc. (US) 2012-06-27 EP claimed
WO-2011022393-A2 PHOSPHATIDYLCHOLINE TRANSFER PROTEIN INHIBITORS THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2011-02-24 WO claimed
US-20190201420-A1 METHODS OF PREVENTION OR TREATMENT FOR PATHOLOGIC THROMBOSIS OR INFLAMMATION THOMAS JEFFERSON UNIVERSITY (US) 2019-07-04 US disclosed
US-9750757-B2 Methods of prevention or treatment for pathologic thrombosis or inflammation THOMAS JEFFERSON UNIVERSITY (US) 2017-09-05 US disclosed
US-9556129-B2 Phosphatidylcholine transfer protein inhibitors THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2017-01-31 US disclosed
US-9556129-B2 Phosphatidylcholine transfer protein inhibitors THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2017-01-31 US disclosed
US-9556129-B2 Phosphatidylcholine transfer protein inhibitors THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2017-01-31 US disclosed
US-20160271150-A1 METHODS OF PREVENTION OR TREATMENT FOR PATHOLOGIC THROMBOSIS OR INFLAMMATION THOMAS JEFFERSON UNIVERSITY (US) 2016-09-22 US disclosed
US-9126938-B2 Phosphatidylcholine transfer protein inhibitors THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2015-09-08 US disclosed
US-9126938-B2 Phosphatidylcholine transfer protein inhibitors THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2015-09-08 US disclosed
US-9126938-B2 Phosphatidylcholine transfer protein inhibitors THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2015-09-08 US disclosed
WO-2015065876-A1 METHODS OF PREVENTION OR TREATMENT FOR PATHOLOGIC THROMBOSIS OR INFLAMMATION THOMAS JEFFERSON UNIVERSITY (US) 2015-05-07 WO disclosed
US-20120264756-A1 Phosphatidylcholine Transfer Protein Inhibitors THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2012-10-18 US disclosed
US-20120264756-A1 Phosphatidylcholine Transfer Protein Inhibitors THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2012-10-18 US disclosed
US-20120264756-A1 Phosphatidylcholine Transfer Protein Inhibitors THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2012-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264756-A1 Phosphatidylcholine Transfer Protein Inhibitors PCTP, LCAT, CETP PCTP 1/4885STARD10 1028/4885STARD7 117/4885
US-20190201420-A1 METHODS OF PREVENTION OR TREATMENT FOR PATHOLOGIC THROMBOSIS OR INFLAMMATION PLAT, F2RL3, PLG PCTP 36/4885STARD10 2235/4885STARD7 1872/4885
US-20160271150-A1 METHODS OF PREVENTION OR TREATMENT FOR PATHOLOGIC THROMBOSIS OR INFLAMMATION PLAT, F2RL3, PLG PCTP 36/4885STARD10 2235/4885STARD7 1872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.